Abstract
In this prospective, non-randomized 6-month observational study we evaluated the efficacy of intravenous immunoglobulin (IVIg) dose increase in patients with multifocal motor neuropathy (MMN). Diagnosis according to AAEM criteria, repetitive IVIg treatment for at least one year, persistent paresis and conduction block, stable symptoms and findings for at least six months were inclusion criteria. Nine patients (7 men) were identified and approved to standardized increase of IVIg dose. Patients were monitored using clinical scores and electrophysiological studies. Dose was increased from a baseline of 0.5 g/kg per month [mean, range: 0.1–1.1], given at variable intervals [4–12 weeks] to 1.2 g/kg per month given over 3 consecutive days planned for 6 cycles. If the patients’ motor function did not improve after two cycles they entered step two: Dose was increased to 2 g/kg per month given over 5 consecutive days. The increased dose was maintained for 6 months. Assessments were performed by the same investigator, not involved in the patient’s management, at baseline, after 2 and after 6 months. Following dose increase, motor function significantly improved in 6 patients (p = 0.014), 2 patients entered step two, 1 patient withdrew due to absent efficacy. Higher doses of IVIg caused more side effects, however, transient and rarely severe (p = 0.014). IVIg dose increase may improve motor functions in patients with stable MMN on long-term IVIg therapy independent of baseline dose. Improvement of motor function was associated with shorter disease duration (p = 0.008), but not with degree of muscle atrophy (p = 0.483). The treatment strategy to try to find the lowest effective dose and the longest tolerated interval might lead to underdosing in the long-term in many patients.
Similar content being viewed by others
References
Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102:177–193
Dalakas MC, Clark WM (2003) Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 60:1736–1737
Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo- controlled study. Neurology 55:1256–1262
Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257–259
Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145–153
Olney RK, Lewis RA, Putnam TD, Campellone JV Jr (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117–121
Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103–107
Sharrack B, Hughes RA (1999) The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5:223–233
Slee M, Selvan A, Donaghy M (2007) Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 69:1680–1687
Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders — a prospective study. J Neurol 250:818–821
Taylor BV, Wright RA, Harper CM, Dyck PJ (2000) Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 23:900–908
Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, Franssen H (2006) Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 77:743–747
Van Asseldonk JT, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Wokke JH, Franssen H (2003) Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 126:186–198
Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH (2002) Multifocal motor neuropathy: longterm clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875–1886
van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA (2006) European Federation of Neurological Societies/ Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 13:802–808
van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005) Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev:CD004429
Vucic S, Black K, Chong PS, Cros D (2007) Multifocal motor neuropathy with conduction block: Distribution of demyelination and axonal degeneration. Clin Neurophysiol 118:124–130
Vucic S, Black KR, Chong PS, Cros D (2004) Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63:1264–1269
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baumann, A., Hess, C.W. & Sturzenegger, M. IVIg dose increase in multifocal motor neuropathy. J Neurol 256, 608–614 (2009). https://doi.org/10.1007/s00415-009-0130-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0130-0